| Filed On | Filing |
|---|---|
| 01 Oct 2026 |
8-K: Regulation FD Disclosure
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress |
| 23 Sep 2026 |
8-K: Regulation FD Disclosure
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress |
| 15 Sep 2026 |
8-K: Regulation FD Disclosure
Evommune Corporate Presentation September 2026 © Evommune, Inc. |
| 09 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
‑ Trial did not meet the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score from baseline at Week 12; EVO756 was generally well tolerated |
| 06 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 30 Jul 2026 | 8-K: Regulation FD Disclosure |
| 29 Jun 2026 | 8-K: Regulation FD Disclosure; Other Events |
| 02 Jun 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 07 May 2026 | 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure |
| 13 Apr 2026 | 8-K: Regulation FD Disclosure |
| 05 Mar 2026 | 8-K: Results of Operations and Financial Condition |
| 13 Feb 2026 | 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more |
| 10 Feb 2026 | 8-K: Regulation FD Disclosure |
| 11 Dec 2025 | 8-K: Results of Operations and Financial Condition |
| 07 Nov 2025 | 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year |
Loading...
